JARID2 Inhibition Reprograms Human Hematopoietic Progenitor Cells To Enhance Bone Marrow Transplantation.

Area of Science:

• Hematology
• Stem Cell Biology
• Epigenetics

Background:

• Hematopoietic stem cell transplantation (HSCT) is crucial for treating blood disorders.
• Umbilical cord blood (UCB) is a vital source of hematopoietic stem and progenitor cells (HSPCs) for HSCT.
• Limited HSPC numbers in UCB restrict its clinical application.

Purpose of the Study:

• To investigate the potential of inhibiting JARID2 to enhance human HSPC function.
• To explore the mechanisms underlying JARID2 inhibition's effects on HSPCs.

Main Methods:

• Utilized constitutive and transient knockdown of JARID2 in human UCB-derived HSPCs.
• Performed in vitro and in vivo functional assays to assess HSPC expansion and self-renewal.
• Analyzed gene expression patterns, including STAT1 and MHC class II immunophenotype.

Main Results:

• JARID2 knockdown significantly increased the number and functionality of human HSPCs.
• The observed phenotype was independent of PRC2 co-factor activity, distinguishing it from EZH2 inhibition.
• JARID2 inhibition induced a quiescent, self-renewal gene expression program involving STAT1 upregulation and an MHC class II immunophenotype.

Conclusions:

• JARID2 inhibition is a novel, reversible strategy to expand functional UCB-derived HSPCs ex vivo.
• This approach holds potential for improving patient access to life-saving stem cell transplantation.
• The findings suggest JARID2 as a therapeutic target for enhancing stem cell therapies.